The question I was addressing was whether the NIBR was more or less economically efficient than a more free-wheeling culture of start-ups failing or succeeding, with the successes transitioning either to "Big Pharma", or becoming bigger themselves.

The author of the article implies that the NIBR approach was more productive, but didn't compare it to an alternative that consumed similar amounts of capital.